{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-039106","form_type":"8-K","ticker":"RAPH","cik":"0001415397","company_name":"Raphael Pharmaceutical Inc.","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.320972+00:00","generated_at":"2026-06-03T00:15:08.848874+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Raphael Pharma launches US proof-of-concept CBG trial for rheumatoid arthritis","bullets":["Proof-of-concept clinical trial begun in US for Cannabigerol (CBG) in active Rheumatoid Arthritis patients.","Engaged MindMate/Citruslabs to oversee trial; estimated timeline 6 months from first participant recruitment.","Trial leverages pre-clinical experiments conducted at Rambam Health Care Campus, Israel.","No financial guidance or material financial impact disclosed in filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-039106","json":"https://secwatch.observer/filing/0001213900-24-039106.json","markdown":"https://secwatch.observer/filing/0001213900-24-039106.md","text":"https://secwatch.observer/filing/0001213900-24-039106.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1415397/000121390024039106/0001213900-24-039106-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1415397/000121390024039106/ea0205172-8k_raphael.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T00:15:08.848874+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}